Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:06:36.238Z.
Calculation as of: 2026-10-06T16:06:36.238Z.
Quote observation: 2026-10-06T16:05:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16291309013886a388882617e5d80f34fb5e9972494eca64a5e5fc74bed8c75f
PEG RATIO
N/A
Benitec Biopharma Inc.
Market Cap
$302.41M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Benitec Biopharma Inc. (BNTC) | $302.41M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.12M | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $309.22M | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.59M | N/A |
| Standard BioTools Inc. (LAB)vs › | $288.98M | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.11M | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.83M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $281.97M | N/A |
| Avita Medical Inc. (RCEL)vs › | $321.10M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $279.98M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
